HonorStocks Biotech Gold Oil Mining China Asian MENU
Biotech Gold Oil Mining China Asian
Find Tomorrow's Winners Today

Stock technical analysis
Rating Flag Rating Flag Rating Flag Rating Flag Rating Flag
sell neutral buy
AstraZeneca PLC (AZN)
58.37  0.02  (0.03%) 06-21 03:30
Open: 57.83 High: 58.6
Pre.close: 58.35 Low: 57.57
Volume: 14,107,314 Ave vol: 8,277,357
52w High: 64.94 52w Low: 46.48
MA(50): 56.309 MA(200): 52.027
EPS: 1.5155 P/E Ratio: 38.52
Company profile
Exchange: NASDAQ
Sector: Healthcare
Industry: Drug Manufacturers—General
Website: http://www.astrazeneca.com
Market Cap (M): 155,231
Shares Out (M): 2,659
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR/Komboglyze, Onglyza, Qtern, Symlin, Xigduo/Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Tudorza/Eklira, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalen and Synagis for infection diseases; Movantik/Moventig, Seroquel IR/Seroquel XR, and Vimovo for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Arcus Biosciences, Inc. to evaluate domvanalimab (AB154), an investigational anti-TIGIT antibody in combination with Imfinzi (durvalumab); and Fusion Pharmaceuticals Inc. to develop and commercialize next-generation alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
Technical analysis
Overall: Underperform
MA: Bullish MACD: Bearish
KDJ: Bearish RSI: Bullish
Target 1: 69.31 Target 2: 80.95
Resist 1: 59.34 Resist 2: 69.31
Support 1: 56.71 Support 2: 55.08
Company key metrics
Revenue per Share: 10.2294
Net Income per Share: 1.2283
Cash per Share: 3.0553
Book Value per Share: 6.01
Price to Sales: 4.9465
Price to Book Value: 8.4193
Earnings Yield: 0.0243
Dividend Yield: 0.0271
Debt to Equity: 1.1194
Debt to Assets: 0.7656
Financial analysis
Price to Book Value: Outperform
Return on Assets: Neutral
Return on Equity: Neutral
Discounted cash flow: Outperform
Price to Earnings: Outperform
Debt to Equity: Outperform
Stock Charts

HonorStocks, Find Tomorrow's Winners Today

©HonorStocks.com | U.S. stock markets, stock quotes and stock analysis. Data and information is provided for informational purposes only, is not intended for trading purposes and is not investment advice. Neither HonorStocks.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Market data provided by: IEX and Financial Modeling Prep

Privacy Policy: Third parties, including Google, may be placing and reading cookies on your browsers, or other methods to collect information as a result of ad serving on this website. Google's use of advertising cookies enables it and its partners to serve ads to you based on your visit to this site and/or other sites on the Internet. You may opt out of personalized advertising by visiting Ads Settings. If you choose to use this website, you agree to the collection and use of information in relation to this policy. The information collected is used for providing and improving the ads Service. We will not use or share information with anyone, and we do not store any data from users.